EXHIBIT B

February 5, 2008

Mr. Patrick Mahaffy
President & Chief Executive Officer
Pharmion Corporation
2525 28th Street
Boulder, CO 80301


Dear Mr. Mahaffy,

We and our affiliates advise funds holding more than 3.1 million shares of
Pharmion Corporation common stock, representing approximately 8.3% of the
outstanding shares. We believe that the proposed merger with Celgene Corporation
would not fairly compensate Pharmion's shareholders. We see the merits of a
potential merger based upon Pharmion's strong commercial products and pipeline
and synergies with Celgene's business. However, we believe that Pharmion's
shareholders would not receive sufficient value for Pharmion's current products
or the opportunity for a higher valuation if competitive data from the Phase III
Dacogen EORTC study does not match data already produced by Pharmion's Vidaza.
Specifically, we believe Pharmion shareholders should be given a higher
consideration to vote for deal prior to seeing the Dacogen data or be allowed to
assess the Dacogen EORTC data prior to voting on the merger.

Based on our own analyses and those in the published research of numerous sell
side analysts, we believe that if Dacogen's survival data are worse than
Vidaza's, Vidaza could capture significantly more than half of the MDS market
and peak sales could be $100 million to $250 million higher than current
projections. If the Dacogen trial fails or produces data that are clearly worse
than Vidaza's survival data, we believe Pharmion would be worth $80 - $100 or
more as a standalone company versus the $72 per share in stock and cash offered
by Celgene. If the proposed merger is completed, Pharmion shareholders' exposure
to this upside will be diluted in Celgene's stock.

We see the merits of a potential merger with Celgene. However, as the merger is
currently proposed, we believe that Pharmion's shareholders would not receive
sufficient value for Pharmion's current products or the opportunity for a higher
valuation if competitive data from Dacogen does not match data already produced
by Pharmion's Vidaza.


Sincerely,

S.A.C. Capital Advisors, LLC